The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Bimekizumab
Biologic
IL-17
Interleukin
Psoriasis
Psoriatic arthritis
Treatment
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
10 Feb 2024
10 Feb 2024
Historique:
received:
06
11
2023
accepted:
12
01
2024
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
10
2
2024
Statut:
aheadofprint
Résumé
Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for treating moderate to severe psoriasis. Limited guidelines exist for incorporating this drug into clinical practice. The purpose of this study was for a panel of experts in psoriasis management to synthesize current literature and provide consensus statements with guidance on use of bimekizumab. A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the use of bimekizumab for moderate to severe psoriasis and psoriatic arthritis. A panel of nine dermatologists with significant expertise in treatment of psoriasis gathered to review the articles and create consensus statements on this new medication. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using Strength of Recommendation Taxonomy criteria. The literature search produced 102 articles that met criteria. A thorough screening of the studies for relevance to the research question resulted in 19 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 14 consensus statements and recommendations, 12 of which were given a strength of "A", one of which was given a strength of "B", and one of which was given a strength of "C". Bimekizumab results in rapid and long-lasting clinical improvement for patients with moderate to severe plaque psoriasis and psoriatic arthritis. It has demonstrated superior efficacy when compared to several other biologics. The safety profile is consistent with other biologics, except for an increased incidence of oropharyngeal candidiasis.
Identifiants
pubmed: 38340237
doi: 10.1007/s13555-024-01099-y
pii: 10.1007/s13555-024-01099-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427. https://doi.org/10.3390/ijms18112427 .
doi: 10.3390/ijms18112427
pubmed: 29144382
pmcid: 5713395
Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–92. https://doi.org/10.2165/00128071-200506060-00005 .
doi: 10.2165/00128071-200506060-00005
pubmed: 16343026
Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012;30(11):1005–13. https://doi.org/10.2165/11591580-000000000-00000 .
doi: 10.2165/11591580-000000000-00000
pubmed: 22994598
Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2021;84(4):1023–9. https://doi.org/10.1016/j.jaad.2020.11.039 .
doi: 10.1016/j.jaad.2020.11.039
pubmed: 33253841
Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD011535.pub2 .
doi: 10.1002/14651858.CD011535.pub2
pubmed: 29271481
pmcid: 6486272
Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. https://doi.org/10.3389/fimmu.2018.01682 .
doi: 10.3389/fimmu.2018.01682
pubmed: 30127781
pmcid: 6088173
Soderstrom C, Berstein G, Zhang W, et al. Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin. AAPS J. 2017;19(4):1218–22. https://doi.org/10.1208/s12248-017-0094-4 .
doi: 10.1208/s12248-017-0094-4
pubmed: 28534291
Pariser D, Frankel E, Schlessinger J, et al. Efficacy of secukinumab in the treatment of moderate to severe plaque psoriasis in the North American subgroup of patients: pooled analysis of four phase 3 studies. Dermatol Ther. 2018;8(1):17–32. https://doi.org/10.1007/s13555-017-0211-4 .
doi: 10.1007/s13555-017-0211-4
Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–31. https://doi.org/10.1136/annrheumdis-2019-215386 .
doi: 10.1136/annrheumdis-2019-215386
pubmed: 31563894
Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther. 2016;6(2):111–24. https://doi.org/10.1007/s13555-016-0121-x .
doi: 10.1007/s13555-016-0121-x
Reis J, Vender R, Torres T. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs. 2019;33(4):391–9. https://doi.org/10.1007/s40259-019-00361-6 .
doi: 10.1007/s40259-019-00361-6
pubmed: 31172372
Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001. https://doi.org/10.1111/bcp.13185 .
doi: 10.1111/bcp.13185
pubmed: 27859546
pmcid: 5401985
Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020;83(5):1367–74. https://doi.org/10.1016/j.jaad.2020.05.105 .
doi: 10.1016/j.jaad.2020.05.105
pubmed: 32473974
Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–86. https://doi.org/10.1016/S0140-6736(21)00126-4 .
doi: 10.1016/S0140-6736(21)00126-4
pubmed: 33549192
Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652–63. https://doi.org/10.1111/bjd.20827 .
doi: 10.1111/bjd.20827
pubmed: 34687214
Kokolakis G, Warren RB, Strober B, et al. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. Br J Dermatol. 2023;188(3):330–40. https://doi.org/10.1093/bjd/ljac089 .
doi: 10.1093/bjd/ljac089
pubmed: 36751950
McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25–37. https://doi.org/10.1016/S0140-6736(22)02302-9 .
doi: 10.1016/S0140-6736(22)02302-9
pubmed: 36493791
Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38–48. https://doi.org/10.1016/S0140-6736(22)02303-0 .
doi: 10.1016/S0140-6736(22)02303-0
pubmed: 36495881
Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–40. https://doi.org/10.1016/S0140-6736(19)33161-7 .
doi: 10.1016/S0140-6736(19)33161-7
pubmed: 32035552
Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277-286.e10. https://doi.org/10.1016/j.jaad.2018.03.037 .
doi: 10.1016/j.jaad.2018.03.037
pubmed: 29609013
Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023;89(3):486–95. https://doi.org/10.1016/j.jaad.2023.04.063 .
doi: 10.1016/j.jaad.2023.04.063
pubmed: 37182701
Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials. JAMA Dermatol. 2022;158(7):735. https://doi.org/10.1001/jamadermatol.2022.1185 .
doi: 10.1001/jamadermatol.2022.1185
pubmed: 35544084
pmcid: 9096693
Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. https://doi.org/10.3389/fmed.2023.1243843 .
doi: 10.3389/fmed.2023.1243843
pubmed: 37614958
Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–8. https://doi.org/10.1111/jocd.15543 .
doi: 10.1111/jocd.15543
pubmed: 36448190
Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–40. https://doi.org/10.1038/jid.2015.208 .
doi: 10.1038/jid.2015.208
pubmed: 26053050
Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Med. 2004;17(1):59–67. https://doi.org/10.3122/jabfm.17.1.59 .
doi: 10.3122/jabfm.17.1.59
Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. In: Practical assessment, research, and evaluation, vol. 12, Article 10. 2019. https://doi.org/10.7275/pdz9-th90 .
Berman B, Ceilley R, Cockerell C, et al. Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified delphi process assessment. SKIN J Cutan Med. 2019;3(5):291–306. https://doi.org/10.25251/skin.3.5.1 .
doi: 10.25251/skin.3.5.1
Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018;78(2):S1–23. https://doi.org/10.1016/j.jaad.2017.09.078 .
doi: 10.1016/j.jaad.2017.09.078
pubmed: 29127053
Richard MA, Barnetche T, Rouzaud M, et al. Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. J Eur Acad Dermatol Venereol. 2014;28:3–12. https://doi.org/10.1111/jdv.12560 .
doi: 10.1111/jdv.12560
pubmed: 24985557
Zakria D, Brownstone N, Berman B, et al. Incorporating prognostic gene expression profile assays into the management of cutaneous melanoma: an expert consensus panel. SKIN J Cutan Med. 2023;7(1):556–69. https://doi.org/10.25251/skin.7.1.1 .
doi: 10.25251/skin.7.1.1
Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. J Dermatol. 2019;46(5):389–98. https://doi.org/10.1111/1346-8138.14834 .
doi: 10.1111/1346-8138.14834
pubmed: 30861182
Özkur E, Kıvanç Altunay İ, Oğuz Topal İ, et al. Switching biologics in the treatment of psoriasis: a multicenter experience. Dermatology. 2021;237(1):22–30. https://doi.org/10.1159/000504839 .
doi: 10.1159/000504839
pubmed: 31865339
Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther. 2022;12(8):1777–92. https://doi.org/10.1007/s13555-022-00760-8 .
doi: 10.1007/s13555-022-00760-8
Gottlieb A, Gratacos J, Dikranian A, et al. Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatol Int. 2019;39(1):121–30. https://doi.org/10.1007/s00296-018-4195-x .
doi: 10.1007/s00296-018-4195-x
pubmed: 30426237
Michelsen B, Diamantopoulos AP, Høiberg HK, Soldal DM, Kavanaugh A, Haugeberg G. Need for improvement in current treatment of psoriatic arthritis: study of an outpatient clinic population. J Rheumatol. 2017;44(4):431–6. https://doi.org/10.3899/jrheum.160973 .
doi: 10.3899/jrheum.160973
pubmed: 28148701
Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. https://doi.org/10.3390/ijms21051690 .
doi: 10.3390/ijms21051690
pubmed: 32121574
pmcid: 7084606
Cole S, Manghera A, Burns L, et al. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. J Allergy Clin Immunol. 2023. https://doi.org/10.1016/j.jaci.2023.03.035 .
doi: 10.1016/j.jaci.2023.03.035
pubmed: 37244461
Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–52. https://doi.org/10.1056/NEJMoa2102383 .
doi: 10.1056/NEJMoa2102383
pubmed: 33891380
Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130–41. https://doi.org/10.1056/NEJMoa2102388 .
doi: 10.1056/NEJMoa2102388
pubmed: 33891379
Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–98. https://doi.org/10.1016/S0140-6736(21)00125-2 .
doi: 10.1016/S0140-6736(21)00125-2
pubmed: 33549193
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. https://doi.org/10.1056/NEJMoa1314258 .
doi: 10.1056/NEJMoa1314258
pubmed: 25007392
Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12(5):321–37. https://doi.org/10.2165/11587890-000000000-00000 .
doi: 10.2165/11587890-000000000-00000
pubmed: 21834597
Zaghi D, Krueger GG, Callis DK. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. J Drugs Dermatol JDD. 2012;11(2):160–7.
pubmed: 22270196
Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749–59. https://doi.org/10.1093/bjd/ljad035 .
doi: 10.1093/bjd/ljad035
pubmed: 36967713
Thaçi D, Vender R, De Rie MA, et al. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023;188(1):22–31. https://doi.org/10.1093/bjd/ljac021 .
doi: 10.1093/bjd/ljac021
pubmed: 36689515
Rodríguez-Cerdeira C, González-Cespón JL, Martínez-Herrera E, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Ital J Dermatol Venereol. 2021. https://doi.org/10.23736/S2784-8671.20.06580-3 .
doi: 10.23736/S2784-8671.20.06580-3
Armstrong AW, Bukhalo M, Blauvelt A. A clinician’s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol. 2016;17(4):329–36. https://doi.org/10.1007/s40257-016-0206-4 .
doi: 10.1007/s40257-016-0206-4
pubmed: 27435194
pmcid: 4963441
Armstrong AW, Blauvelt A, Mrowietz U, et al. A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17. Dermatol Ther. 2022;12(3):787–800. https://doi.org/10.1007/s13555-022-00687-0 .
doi: 10.1007/s13555-022-00687-0
Kessler SQS, Lang PM, Dal-Pizzol TS, Montagner F. Resistance profiles to antifungal agents in Candida albicans isolated from human oral cavities: systematic review and meta-analysis. Clin Oral Investig. 2022;26(11):6479–89. https://doi.org/10.1007/s00784-022-04716-2 .
doi: 10.1007/s00784-022-04716-2
pubmed: 36167858
pmcid: 9514684
Van Der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023. https://doi.org/10.1136/ard-2022-223595 .
doi: 10.1136/ard-2022-223595
pubmed: 38071514
Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417. https://doi.org/10.1001/jamadermatol.2018.3631 .
doi: 10.1001/jamadermatol.2018.3631
pubmed: 30422277
pmcid: 6583370
Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med. 2021;290(2):257–78. https://doi.org/10.1111/joim.13282 .
doi: 10.1111/joim.13282
pubmed: 33942408
Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700. https://doi.org/10.1136/gutjnl-2011-301668 .
doi: 10.1136/gutjnl-2011-301668
pubmed: 22595313